

# Ramapo College Immunization Requirements

## **DUE DATE**

Fall Semester Start: July 31st

Spring Semester Start: January 2<sup>nd</sup>

### **IMMUNIZATION POLICY**

Failure to complete health requirements will result in a registration hold.

All registered students are required to submit this form if you are taking classes (in person, online, or virtual).

## REQUIRED IMMUNIZATION FORMS

- 1. Take this packet to your health care provider to be completed, signed, and stamped. This form does not have to be used; an official immunization record from your doctor, employer, military, hospital, or previous school can be submitted. Please make sure that all the required information is provided if you are not using this form.
- 2. Once you have obtained your immunization documents, please submit your immunization forms to Health Services via email (immunize@ramapo.edu) or fax at 201-684-7534 or 201-684-7974.
- 3. If you are age 31 or older at the time of admission to Ramapo College of New Jersey, you are exempt from the immunization requirements under NJ State Law.





## **IMMUNIZATION RECORD**

Ramapo Student ID:
R00

PART 1: COMPLETED BY THE STUDENT. All information must be printed legibly or form cannot be processed.						
Last Name:		First Name:			Middle Initial:	
DOB:		Start Date:Fall _ Year:	art Date:Fall Spring ear:		Cell Number:	
Full-time (12 or more credits) YesNo		Resident Commute	sident Commuter		Residing in the U.S. with a student visaYes No	
DADT	2. TO DE COMDI ETED AND	SIGNED BY VOLID	UEALTI		E DDOVIDED	
A.	PART 2: TO BE COMPLETED AND SIGNED BY YOUR HEALTH CARE PROVIDER.  A. TUBERCULOSIS—PLEASE SEE ATTACHMENT 1 TO COMPLY WITH THIS REQUIREMENT. ALL STUDENTS MUST UPLOAD ATTACHMENT 1 ALONG WITH THIS FORM.					
B.	MMR (Measles, Mumps, Rubella)—Two doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED).					
	1 <sup>st</sup> dose (given at or after 1 <sup>st</sup> birthday): 2 <sup>nd</sup> do		2 <sup>nd</sup> dose	se:		
C.	HEPATITIS B—Completion of three doses of vaccine OR titers showing immunity (COPY OF LAB REPORT REQUIRED). Note: Negative titers will require the student to repeat the series with 3 doses of Hep B.					
	1 <sup>st</sup> dose date:	<sup>2nd</sup> dose:	;	3 <sup>rd</sup> dose	:	
D.	MENINGOCOCCAL ACWY—Required for all students residing on campus AND all commuters 18 years old and younger. Dose must be given at or after the age of 16. Visit <a href="https://www.ramapo.edu/health/meningitis-information/">https://www.ramapo.edu/health/meningitis-information/</a> for more information on Meningitis.					
	Dose date(s):					
Е	RECOMMENDED: MENINGOCOC	CAL B (Trumemba, Be	exsero):			
	1 <sup>st</sup> Dose:	2 <sup>nd</sup> Dose:		3 <sup>rd</sup> [	Dose:	
F.	HEALTH CARE EXAMINER'S STATEMENT: I HAVE VERIFIED THAT THE INDIVIDUAL I HAVE EXAMINED IS THE NAMED INDIVIDUAL ON THIS FORM AND THAT THE ABOVE TESTS/VACCINATIONS WERE PERFORMED IN THIS OFFICE/LABORATORY, OR I HAVE REVIEWED ANY DOCUMENTATION RELATIVE TO THE STUDENT'S IMMUNIZATION RECORD.					
	License #:	Phone	e #:			
	Signature of Healthcare Examiner:				Date:	
PART 3: TO BE SIGNED BY THE STUDENT—FORM CANNOT BE PROCESSED WITHOUT STUDENT SIGNATURE.						
	t Signature:	Rama	Ramapo Student ID:			
The information provided on this form is correct. I understand that failure to complete this form correctly may jeopardize my student standing at Ramapo College. I will submit the form using the directions provided on information						

PLEASE VISIT <a href="https://www.ramapo.edu/health/immunization-info/">https://www.ramapo.edu/health/immunization-info/</a> FOR ANY UPDATES REGARDING RAMAPO COLLEGE'S IMMUNIZATION REQUIREMENTS.



## **TOOL FOR INSTITUTIONAL USE-ATTACHMENT 1**

## Part I: Tuberculosis (TB) Screening Questionnaire (to be completed by incoming students)

Please answer the following qu	estions (1 through 6):		
1. Have you ever had close conta	ct with persons known or suspec	eted to have active TB disease?	☐ Yes ☐ No
2. Were you born in one of the co	untries or territories listed below	that have a high incidence of active TI	B disease?
(If yes, please CIRCLE the counti		· ·	☐ Yes ☐ No
Algeria	Djibouti	Malawi	Senegal
Angola	Dominican Republic	Malaysia	Sierra Leone
Argentina	Ecuador	Maldives	Singapore
Armenia	El Salvador	Mali	Solomon Islands
Azerbaijan	Equatorial Guinea	Marshall Islands	Somalia
Bangladesh	Eritrea	Mauritania	South Africa
Belarus	Eswatini	Mexico	South Sudan
Belize	Ethiopia	Micronesia	Sri Lanka
Benin	Fiji	Mongolia	Sudan
Bhutan	Gabon	Morocco	Suriname
Bolivia (Plurinational State of)	Gambia	Mozambique	Tajikistan
Bosnia and Herzegovina	Georgia	Myanmar	Thailand
Botswana	Ghana	Namibia	Timor-Leste
Brazil	Guatemala	Nauru	Togo
Brunei Darussalam Burkina Faso	Guinea Riasau	Nepal	Tunisia
Burundi	Guinea-Bissau Guyana	Nicaragua Niger	Turkmenistan Tuvalu
Cabo Verde	Haiti	Nigeria	Uganda
Cambodia	Honduras	Niue	Ukraine
Cameroon	India	Pakistan	United Republic of Tanzania
Central African Republic	Indonesia	Palau	Uruguay
Chad	Iraq	Panama	Uzbekistan
China	Kazakhstan	Papua New Guinea	Vanuatu
China, Hong Kong SAR	Kenya	Paraguay	Venezuela (Bolivarian
China, Macao SAR	Kiribati	Peru	Republic of)
Colombia	Kyrgyzstan	Philippines	Vietnam
Comoros	Lao People's Democratic	Qatar	Yemen
Congo	Republic	Republic of Korea	Zambia
Côte d'Ivoire	Lesotho	Republic of Moldova	Zimbabwe
Democratic People's	Liberia	Romania	
Republic of Korea	Libya	Russian Federation	
Democratic Republic of the	Lithuania Madagascar	Rwanda Sao Tome and Principe	
Congo Source: World Health Organization Global Health	O .	vith average incidence rates of ≥ 20 cases per 100,000 p	opulation.
-	to one or more of the countries	or territories listed above for a period	<u></u>
<ol><li>Have you been a resident and/ term care facilities, and homeless</li></ol>		gate settings (e.g., correctional facilitie	s, long- Yes No
5. Have you been a volunteer or h TB disease?	nealth care worker who served cl	ients who are at increased risk for acti	ve Yes No
		at may have an increased incidence oved, low-income, or abusing drugs or	
	- · · · · · · · · · · · · · · · · · · ·	College requires that you receive TB should be discussed with a health car	<b>-</b> -
If the answer to all of the above	e questions is NO, no further tes	ting or further action is required. You	may stop here.
Student's printed name and signature (required):		Date	
ana signature (required)		Date	•



### Part II: Clinical Assessment to be completed by Health Care Provider

Clinicians should review and verify the information in Part I. Persons who answered NO to all questions in Part I do not need further testing. Persons who answered YES to any of the questions in Part I are candidates for either the Mantoux tuberculin skin test (TST) or the Interferon Gamma Release Assay (IGRA), unless a previous positive test has been documented.

ı ıu.	bootii c	ocumented.					
		story of a positive TB skin test or IGRA blood test? (If yes, document below.) story of BCG vaccination? (If yes, consider IGRA if possible.)	Yes T	No No			
				INO			
1.	TB SY	MPTOM CHECK					
		ne student have signs or symptoms of active pulmonary tuberculosis disease?	Yes	No			
	If No, p	proceed to 2 or 3.					
	If Yes,	check below:					
	0	Cough (especially if lasting for 3 weeks or longer) with or without sputum produ	uction				
	0	Coughing up blood (hemoptysis)					
	0	Chest pain					
	0	Loss of appetite					
	0	Unexplained weight loss					
	0	Night sweats					
	0	Fever					
	Pro	oceed with additional evaluation to exclude active tuberculosis disease, including	ງ tuberculin ski	in testing,			
	ch	est X-ray, and sputum evaluation as indicated.					
2.		RCULIN SKIN TEST (TST): MUST BE PERFORMED IN THE UNITED STATES	(IF CURREN	TLY LIVING			
		DE OF THE UNITED STATES, GO TO #3).					
	(TST r	(TST result should be recorded as actual millimeters [mm] of induration, transverse diameter; if no induration,					
	write "(	)." The TST interpretation should be based on mm of induration as well as risk fa	actors.)**				
		•	•				

## \*\*INTERPRETATION GUIDELINES

Result: mm of induration

Date Given:\_\_\_/\_\_\_/

### >5 mm is positive:

- Recent close contacts of an individual with infectious TB
- Persons with fibrotic changes on a prior chest X-ray, consistent with past TB disease
- Organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15mg/d of prednisone for >1 month)

Date Read: \_\_\_\_/\_\_\_\_

\*\*Interpretation: positive\_\_\_\_ negative\_\_\_\_

HIV-infected persons

## > 10 mm is positive:

- Recent arrivals to the U.S. (<5 years) from high-prevalence areas or who resided in one for a significant
  amount of time (The significance of the travel exposure should be discussed with a health care provider
  and evaluated.)</li>
- Injection drug users
- Mycobacteriology laboratory personnel
- Residents, employees, or volunteers in high-risk congregate settings
- Persons with medical conditions that increase the risk of progression to TB disease, including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

## >15 mm is positive:

 Persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested.



	INTERFERON GAMMA RELEASE ASSAY (IGRA): MAY BE COMPLETED OUTSIDE OF THE UNITED STATES BUT LAB REPORT IS REQUIRED IN ENGLISH.
[	Date Obtained:/ (circle method) QFT-GIT T-Spot other
F	Result: negative positive indeterminate borderline (T-Spot only)
	CHEST X-RAY: REQUIRED IF TST OR IGRA IS POSITIVE (Radiology report is required in English).
	Note: a single  Date of chest X-ray:/ Result: normal abnormal
- Part	III: Management of Positive TST or IGRA
All st	tudents with a positive TST or IGRA with no signs of active disease on chest X-ray should receive a
	mmendation to be treated for latent TB with appropriate medication. However, students in the following groups
	at increased risk of progressions from LTBI to TB disease and should be prioritized to begin treatment as soon as
poss	Infected with HIV
	Recently infected with M. tuberculosis (within the past 2 years)
	<ul> <li>History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest</li> </ul>
	radiograph consistent with prior TB disease
	Receiving immunosuppressive therapy, such as tumor necrosis factor-alpha (TNF) antagonists, systemic
	corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug
	therapy following organ transplantation
	<ul> <li>Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung</li> </ul>
	Have had a gastrectomy or jejunoileal bypass
	Weigh less than 90% of their ideal body weight
	Cigarette smokers and persons who abuse drugs and/or alcohol
]	Student agrees to receive treatment
	Student declines treatment at this time
ealth C	Care Professional
ignatu	

